Newsletter Subject

Double Your Money in the AM?

From

tradinggeniuscenter.com

Email Address

newsletter@tradinggeniuscenter.com

Sent On

Thu, Apr 21, 2022 06:03 PM

Email Preheader Text

April 21, 2022 Big Pharma bought each of these companies because of their new cancer treatments. And

April 21, 2022 [Trading Genius Center] From time to time, we come across offers that you may find interesting: Dear Friend, Can you imagine doubling your money in one morning? It's happened 3 times in the past 6 months with takeovers. On May 4th, 2020, investors made 154% in one morning - when Stemline Therapeutics was taken over. On March 4, 2020, investors made 147% in one morning - when Forty-Seven was taken over by Gilead. And on December 9, 2019 investors made 100% in one morning - when Arqule was taken over by Merck. [Here's the next biotech we think gets taken over ]( Big Pharma bought each of these companies because of their new cancer treatments. And takeover master Dylan Jovine has just released the next biotech he thinks gets taken over. This tiny biotech recently signed a deal with Bristol-Myers - because of their powerful new cancer treatment. Dylan Jovine is an expert when it comes to picking biotech takeovers: On August 19, 2019, investors made 144% in one morning - when Array Biopharma was taken over by Pfizer. On October 1st of 2018, investors made 91% in one morning - when Tesaro was taken over by Glaxo. On January 4th, 2019, investors made 71% in one morning - when Loxo Oncology was taken over by Eli Lilly. [Get the next biotech he think gets taken over ]( Sincerely, Simmy Adelman, Editor Behind the Markets This third party offer is brought to you by Trading Genius Center. 483 GREEN LANES, LONDON, N134BS, UK. If you would like to unsubscribe from receiving offers, [click here.]( To file an email abuse complaint, please [click here.]( [Please Read Our Privacy Policy]( To ensure you receive our emails, be sure to whitelist us. [Unsubscribe]( | [View In Browser]( © Copyright 2022. All Rights Reserved.

Marketing emails from tradinggeniuscenter.com

View More
Sent On

29/04/2022

Sent On

29/04/2022

Sent On

28/04/2022

Sent On

28/04/2022

Sent On

27/04/2022

Sent On

27/04/2022

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2024 SimilarMail.